515153-81-8

Upstream product

• 78-39-7 Triethyl orthoacetate 
• 82998-57-0 3-iodo-4-toluic acid 
• 90347-66-3 methyl 3-iodo-4-methylbenzoate 

Downstream Products

• 1190863-17-2 [2-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]boronic acid 
• 1190860-97-9 6'-(2-Methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)spiro[cyclopentane-1,3'-indolin]-2'-one 

Relevant academic research and scientific papers

New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives

This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), to pharmaceutical compositions comprising them, and to their use in therapy.

NEW 7-PHENYL-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE DERIVATIVES

This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), to processes for their preparation, to pharmaceutical compositions comprising them, and to their use in therapy.

Indolin-2-one p38α inhibitors III: Bioisosteric amide replacement

Crystallographic structural information was used in the design and synthesis of a number of bioisosteric derivatives to replace the amide moiety in a lead series of p38a inhibitors which showed general hydrolytic instability in human liver preparations. Triazole derivative 13 was found to have moderate bioavailability in the rat and demonstrated potent in-vivo activity in an acute model of inflammation.

New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors

This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.